# US 2001/0044428 A1 · Aminopyridines and methods of using thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0044428 A1
- Document ID: US20010044428A1
- Status: Published application
- Kind: A1
- Application number: 09/819,693
- Filed: 2001-03-29
- Published: 2001-11-22
- Earliest claimed: 2000-03-31
- Assignees: CoCensys, Inc.
- Inventors: Derk J. Hogenkamp
- Web page: https://patentgrep.com/patent/US20010044428A1

## CPC

- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 23/02: Local anaesthetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to aminopyridines of Formula I: 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R1-R8, X and m are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

## Claims

### Claim 1

A compound having the Formula I:
5
or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:
R1 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, haloalkyl, cycloalkyl, amino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, carboxyalkyl, cyano, alkylamino, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, alkylcarbonyl, heterocyclocarbonyl, aminosulfonyl, alkylaminosulfonyl, and heterocyclosulfonyl, all of which can be optionally substituted;
R2 is hydrogen or C1-6 alkyl and R3 is hydrogen, or R2 and R3 together form a bond;
R4 is hydrogen or C1-6 alkyl;
R5, R6, R7, and R8 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, haloalkyl, hydroxyalkyl, hydroxy, nitro, amino, aminoalkyl, cyano, amide, carboxyalkyl, alkoxyalkyl, ureido, acylamino, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido and alkylthiol;
X is one of O, S, NR9, or CH2, wherein R9 is hydrogen or alkyl; and
m is 0-3.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is selected from the group consisting of independently selected from the group consisting of hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, amino(C1-C6)alkyl, amino, C1-C6 alkylthio, cyano, C1-C6 alkylsulfinyl, hydroxy(C1-C6)alkyl, C1-C6 alkoxy, aminocarbonyl, C1-C6 alkylaminocarbonyl, C6-C10 arylaminocarbonyl, C6-C10 aryl(C1-C6)alkylamino-carbonyl, C1-C6 alkylcarbonylamino, C6-C10 arylcarbonylamino, C6-C10 aryl(C1-C6)alkylcarbonylamino, C1-C6 alkylcarbonyl, heterocyclocarbonyl, aminosulfonyl, C1-C6 alkylaminosulfonyl, C1-C6 alkylsulfonyl, and heterocyclosulfonyl.

### Claim 3 (depends on 2)

The compound of claim 2, wherein R1 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxy, amino(C1-C6)alkyl, C1-C6 alkylthio and aminocarbonyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R5, R6, R7, and R8 are independently selected from the group consisting of hydrogen, halo, C1-C6 haloalkyl, C6-C10 aryl, C4-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C10 aryl(C1-C6)alkyl, C6-C10 aryl(C2-C6)alkenyl, C6-C10 aryl(C2-C6)alkynyl, C1-C6 hydroxyalkyl, nitro, amino, ureido, cyano, C1-C6 acylamido, hydroxy, thiol, C1-C6 acyloxy, azido, C1-C6 alkoxy, or carboxy.

### Claim 5 (depends on 4)

The compound of claim 4, wherein R5 and R6 are both hydrogen, R7 is hydrogen and R8 is a fluoro in the meta- or para-position.

### Claim 6 (depends on 1)

The compound of claim 1, wherein X is O or S.

### Claim 7 (depends on 6)

The compound of claim 6, wherein X is O.

### Claim 8 (depends on 1)

The compound of claim 1, having the Formula II:
6
wherein R1, R4, and R5-R8 are as defined in claim 1, X is O or S and m is 0 or 1.

### Claim 9 (depends on 8)

The compound of claim 8, wherein R1 is selected from the group consisting of hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, amino(C1-C6)alkyl, amino, C1-C6 alkylthio, cyano, C1-C6 alkylsulfinyl, hydroxy(C1-C6)alkyl, C1-C6 alkoxy, aminocarbonyl, C1-C6 alkylaminocarbonyl, C6-C10 arylaminocarbonyl, C6-C10 aryl(C1-C6)alkylamino-carbonyl, C1-C6 alkylcarbonylamino, C6-C10 arylcarbonylamino, C6-C10 aryl(C1-C6)alkylcarbonylamino, C1-C6 alkylcarbonyl, heterocyclocarbonyl, aminosulfonyl, C1-C6 alkylaminosulfonyl, C1-C6 alkylsulfonyl, and heterocyclosulfonyl.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R1 is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxy, amino(C1-C6)alkyl, C1-C6 alkylthio and aminocarbonyl.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R5, R6, R7, and R8 are independently selected from the group consisting of hydrogen, halo, C1-C6 haloalkyl, C6-C10 aryl, C4-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C6-C10 aryl(C1-C6)alkyl, C6-C10 aryl(C2-C6)alkenyl, C6-C10 aryl(C2-C6)alkynyl, C1-C6 hydroxyalkyl, nitro, amino, ureido, cyano, C1-C6 acylamido, hydroxy, thiol, C1-C6 acyloxy, azido, C1-C6 alkoxy, or carboxy.

### Claim 12 (depends on 11)

The compound of claim 11, wherein R5 and R6 are both hydrogen, R7 is hydrogen and R8 is a fluoro in the meta- or para-position.

### Claim 13 (depends on 1)

The compound of claim 1, wherein said compound is:
N3-[4-(3-fluorobenzyloxy)benzyl]pyridine-2,3-diamine;
N3-[4-(3-fluorobenzyloxy)benzylidene]pyridine-2,3-diamine;
N3-[4-(4-fluorophenoxy)benzyl]pyridine-2,3-diamine; or
N3-[4-(4-fluorophenoxy)benzylidene]pyridine-2,3-diamine;
or a pharmaceutically acceptable salt, prodrug or solvate thereof.

### Claim 14 (depends on 1)

A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

### Claim 15 (depends on 1)

A method of treating a disorder responsive to the blockade of sodium channels in a mammal suffering therefrom, comprising administering to a mammal in need of such treatment an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof.

### Claim 16 (depends on 1)

A method for treating, preventing or ameliorating neuronal loss following global and focal ischemia; treating, preventing or ameliorating neurodegenerative conditions; treating, preventing or ameliorating pain or tinnitus; treating, preventing or ameliorating manic depression; providing local anesthesia; or treating arrhythmias, or treating convulsions, comprising administering to a mammal in need of such treatment an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the method is for treating, preventing or ameliorating pain and said pain is one of neuropathic pain, surgical pain or chronic pain.

### Claim 18 (depends on 1)

A method of alleviating or preventing seizure activity in an animal subject, comprising administering to said animal in need of such treatment an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt, prodrug or solvate thereof.

### Claim 19 (depends on 1)

A compound of claim 1, wherein said compound is 3H or 14C radiolabeled.

### Claim 20 (depends on 19)

Use of a compound of claim 19 as a radioligand for its binding site on the sodium channel.
